FIELD: diagnostics of diseases.
SUBSTANCE: composition for optical imaging of a mammal's body, a method of its preparation, a pharmaceutical composition and a method of in vivo optical imaging of a mammal's body are proposed. A lyophilized composition for use in imaging cMet overexpression or localization sites contains 4 to 12% by weight of an active pharmaceutical ingredient (API) of Formula I, comprising at least one cMet binding peptide, 3 to 35% by weight of a buffering agent, and 56 to 91% by weight of lyoprotector. When the composition is re-dissolved it has a pH of 6.8 to 9. The formulation is used for in vivo imaging and for cMet quantification assays in biological samples or cMet imaging in tissue samples.
EFFECT: inventions provide obtaining a stable for a long period of time composition for optical imaging, which has a good recovery when diluted at appropriate pH and tonicity for intravenous use.
42 cl, 1 dwg, 10 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MARKED PEPTIDES BINDING HEPATOCYTE GROWTH FACTOR (HGF) FOR VISUALISATION | 2008 |
|
RU2473361C9 |
| PEPTIDE COMPOSITION OF RADIOACTIVE INDICATORS | 2011 |
|
RU2594167C2 |
| FORMULATIONS BASED ON CD19 ANTIBODY | 2017 |
|
RU2748024C2 |
| CONJUGATES OF CMET ANTIBODY AND DRUG AND METHODS OF USING | 2017 |
|
RU2740996C2 |
| INSULIN AND ITS DERIVATIVES WITH ENHANCED CAPACITY TO BIND ZINC | 1997 |
|
RU2176646C2 |
| INSULIN ANALOGUE COMPLEX WITH REDUCED AFFINITY TO INSULIN RECEPTOR AND ITS USE | 2018 |
|
RU2779462C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE | 2018 |
|
RU2782792C2 |
| COMBINED FORMULATIONS OF ANTI-LAG3 ANTIBODY AND ANTI-PD-1 ANTIBODY | 2019 |
|
RU2822192C2 |
| MONOCLONAL BINDING AGENTS, THEIR DRUG CONJUGATES AND THEIR APPLICATIONS | 2017 |
|
RU2744914C2 |
| COMPOSITION CONTAINING ANTIBODY | 2019 |
|
RU2806628C2 |
